A Study of E6011 in Participants With Active Crohn's Disease
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to examine the efficacy and safety of E6011 at 12 weeks
after administration by means of double-blind placebo-controlled trial.